Dr. Kerry Rogers, a CLL expert and associate professor at Ohio State University, shared findings with us at the 2023 ASH conference from a study that discussed how a medicine called lenalidomide helped CLL patients. Watch her interview or read the summary of her research below.
Lenalidomide (Revlimid) is a medication primarily used in treating multiple myeloma and diffuse large B-cell lymphoma. Interestingly, it's also effective in CLL, though it's not commonly used for this type of blood cancer.
Over a decade ago, researchers at Dr. Rogers' institution began a study involving CLL patients who did not yet need traditional treatment. Typically, CLL patients are observed until they develop significant symptoms like enlarged lymph nodes or low blood counts. This study involved patients with high-risk CLL features, meaning they were likely to need treatment soon but were not there yet. These individuals were given lenalidomide, despite it not being a standard CLL treatment.
The results from the study showed:
As a CLL patient, knowing about these developments is empowering. It means:
Dr. Rogers stated that in the future, she would like to see more research on treating CLL patients with low doses of lenalidomide, such as in cases where CLL patients receive lenalidomide while in watch-and-wait, or as a follow-up therapy after standard CLL treatment to help them remain in remission.
In conclusion, Dr. Kerry Rogers' research on lenalidomide offers new hope and possibilities for CLL patients. Staying informed about such developments is important in understanding your treatment options and discussing them with your healthcare provider.
Are you interested in accelerating research toward a cure for CLL? We have created a powerful patient data portal named HealthTree Cure Hub for this very purpose. We invite you to join the 12,000-and-counting blood cancer patients who are collaborating with specialists through research surveys and studies in HealthTree Cure Hub. YOU are the key to improving CLL care. We are grateful for your time and support in helping us progress toward a CLL cure. Create your free HealthTree Cure Hub account by visiting the link below!
Dr. Kerry Rogers, a CLL expert and associate professor at Ohio State University, shared findings with us at the 2023 ASH conference from a study that discussed how a medicine called lenalidomide helped CLL patients. Watch her interview or read the summary of her research below.
Lenalidomide (Revlimid) is a medication primarily used in treating multiple myeloma and diffuse large B-cell lymphoma. Interestingly, it's also effective in CLL, though it's not commonly used for this type of blood cancer.
Over a decade ago, researchers at Dr. Rogers' institution began a study involving CLL patients who did not yet need traditional treatment. Typically, CLL patients are observed until they develop significant symptoms like enlarged lymph nodes or low blood counts. This study involved patients with high-risk CLL features, meaning they were likely to need treatment soon but were not there yet. These individuals were given lenalidomide, despite it not being a standard CLL treatment.
The results from the study showed:
As a CLL patient, knowing about these developments is empowering. It means:
Dr. Rogers stated that in the future, she would like to see more research on treating CLL patients with low doses of lenalidomide, such as in cases where CLL patients receive lenalidomide while in watch-and-wait, or as a follow-up therapy after standard CLL treatment to help them remain in remission.
In conclusion, Dr. Kerry Rogers' research on lenalidomide offers new hope and possibilities for CLL patients. Staying informed about such developments is important in understanding your treatment options and discussing them with your healthcare provider.
Are you interested in accelerating research toward a cure for CLL? We have created a powerful patient data portal named HealthTree Cure Hub for this very purpose. We invite you to join the 12,000-and-counting blood cancer patients who are collaborating with specialists through research surveys and studies in HealthTree Cure Hub. YOU are the key to improving CLL care. We are grateful for your time and support in helping us progress toward a CLL cure. Create your free HealthTree Cure Hub account by visiting the link below!
about the author
Megan Heaps
Megan joined HealthTree in 2022. As a writer and the daughter of a blood cancer patient, she is dedicated to helping patients and their caregivers understand the various aspects of their disease. This understanding enables them to better advocate for themselves and improve their treatment outcomes. In her spare time, she enjoys spending time with her family.
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.